0001104659-26-057545
SEC filingNet loss narrowed as the company reduced operating cash burn, though the pre-revenue biotech continues to consume cash while advancing its pipeline.
Net loss for the first quarter of 2026 was $4.6 million, compared to $8.5 million for the same period in 2025, a 46% improvement. The reduction in net loss was primarily driven by lower research and development expenses and general and administrative expenses, reflecting the company's ongoing cost discipline as it advances its pipeline of therapies for neurodegenerative diseases.
Net cash used in operating activities was $5.5 million for the first quarter of 2026, compared to $9.9 million for the same period in 2025. The decrease in cash burn was attributable to lower operating expenses. The company expects to continue to incur losses for the foreseeable future as it invests in research and development. Management anticipates that general and administrative expenses will increase as headcount grows to support expanded R&D activities.
The company has lease agreements that require monthly rent payments in advance, with additional rent payable on demand for certain costs. These obligations are classified as operating costs and are included in the company's cash flow projections. The company must maintain the premises and restore fixtures to original condition upon lease termination, which could result in future cash outflows.
Cognition Therapeutics remains a pre-revenue biotech focused on developing treatments for Alzheimer's disease and other cognitive disorders. The company's ability to fund operations depends on its cash reserves and future financing activities. While the reduction in net loss and operating cash burn demonstrates improved cost management, the company will need to continue raising capital to support its clinical programs and general operations.